Trigeminy Premature Ventricular Beatrelated to Osimertinib for an EGFR Exon19del Mutation Lung Adenocarcinoma

Non-small cell lung cancer benefit a lot based on the targetable oncogenic gene detection and subsequent tyrosine kinase inhibitor (TKI). However, adverse event administration was a new challenge for treatment management strategies. Previous studies demonstrated a third generation epidermal growth factor receptor (EGFR) osimertinib to be high efficacy and well tolerant in EGFR mutation positive NSCLC with or without T790M mutation...